What question did this study set out to answer?

The study aims to evaluate the effectiveness of MRI markers in classifying progressive supranuclear palsy (PSP) compared to other neurodegenerative disorders.

June 4, 2026Open Access

Planimetric and Linear MRI Markers for Progressive Supranuclear Palsy Classification: A Large Multicohort International Study

Puntos clave

The study aims to evaluate the effectiveness of MRI markers in classifying progressive supranuclear palsy (PSP) compared to other neurodegenerative disorders.
Conducted a multicohort international study with large participant numbers.
Utilized planimetric and linear MRI markers for analysis.
Registration in clinical trials NCT03068468, NCT01110720, NCT01049399, NCT01804452.
The DMPI and midbrain area markers showed high effectiveness for differentiating PSP from other neurodegenerative parkinsonisms (AUC, 0.94 [95% CI: 0.86, 1.00]).

Resumen

= 43) (AUC, 0.94 95% CI: 0.86, 1.00). Conclusion The DMPI and midbrain area performed well for differentiating PSP from other neurodegenerative parkinsonisms. Clinical trial registration nos. NCT03068468, NCT01110720, NCT01049399, NCT01804452 © The Author(s) 2026. Published by the Radiological Society of North America under a CC BY 4.0 license.

Leer artículo completoexternamente

Me gusta

Guardar

Ver artículo completo

Cite This Study

Quattrone et al. (Mon,) studied this question.

synapsesocial.com/papers/6a2116cfd499ed480b16fb3d https://doi.org/https://doi.org/10.1148/radiol.251394

Me gusta

Guardar

Ver artículo completo